PTGES3L-AARSD1

Across TCGA pan-cancer cohorts, PTGES3L-AARSD1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PTGES3L-AARSD1 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PTGES3L-AARSD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTGES3L-AARSD1 expression acts as an unfavorable survival marker.

UCEC and SKCM are the cancer types where PTGES3L-AARSD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.159	0.600	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PTGES3L-AARSD1–UCEC (OS)

Open the UCEC breakdown →